BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22110898)

  • 41. Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia.
    Tsumura Y; Yamada Y; Osumi T; Kato M; Terashima K; Shioda Y; Kiyotani C; Matsumoto K; Tomizawa D
    J Pediatr Hematol Oncol; 2020 May; 42(4):322-325. PubMed ID: 30807394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    Lachaine J; Mathurin K; Barakat S; Couban S
    Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retinoic acid syndrome.
    Datta D; Gerardi DA
    Conn Med; 2003 Oct; 67(9):541-3. PubMed ID: 14619342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
    Zhang X; Liu L; Yao Y; Gong S; Wang M; Xi J; Chen L; Wei S; Zhang H; Zhao C; Wang H
    Trials; 2020 Jan; 21(1):7. PubMed ID: 31898521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells.
    Sumi D; Suzukawa K; Himeno S
    Life Sci; 2016 Mar; 149():42-50. PubMed ID: 26892147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
    Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of arsenic trioxide, all-trans-retinoic acid and dexamethasone on NB4 cell line.
    Mandegary A; Mehrabani M
    Daru; 2010; 18(4):303-9. PubMed ID: 22615633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [